NATHAN VALENTINE: Open Payments
NPI 1154707552 · ABERDEEN, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$983 in 54 payments from 12 companies in 2025. Trend: 2023 $986 · 2024 $967 · 2025 $983
Food & beverage: $983
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $178 |
| Amgen Inc. | 13 | $173 |
| GlaxoSmithKline, LLC. | 7 | $153 |
| PFIZER INC. | 9 | $143 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $91 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $63 |
| Phathom Pharmaceuticals, Inc. | 3 | $45 |
| Novo Nordisk Inc | 2 | $42 |
| Viatris Specialty LLC | 2 | $40 |
| Abbott Laboratories | 1 | $20 |
Products named: TRELEGY ELLIPTA, OTEZLA, AIRSUPRA, XIFAXAN, PAXLOVID, JARDIANCE, BREZTRI, VOQUEZNA.
Industry payments across WA — which companies pay providers there.
